Member Info for spike912

The ask has dropped to £1.06 so sell and still NT to sell

CB not sure given it’s NT to sell unless auction

£1.10 looking to fall

Can buy fine on Halifax

Spurge if trades now back to sleep lol

Either way it’s a hell of a lot more than the current mcap and free cash flow. No brainer

Moving now! Someone’s knocking at the door....someone’s ringing the bell ;)

Has the market not seen this yet? Seems low start

Maybe intraday, who knows, had a few of those recently

Tick tock Dave

Jimzi 20:29 summed up well. Exactly. Too many school boy errors on aim RNSs

Jay, I depends on your view of negative I guess. The longer route to approval the more likely a raise is on the cards, and let’s face it, as 5-7p area is going to cause dilution to a level which will hurt us. Whilst all options may be “workable”, let’s not forget the current cash position. My guess would be they are hoping for good news, lift the SP and then raise However what happens if the news is a lengthy delay, SP sinks, then we are raising as sub 5p at best (only a theory). Either way, imo, we are facing a raise one way or another

Thanks ST Looks like forget news next week :(

Didn’t Rathlin confirm we were ahead?

Stebol I think ultimately it comes down to very poor comms and poorly worded RNSs by the bod. They haven’t helped themselves here which has led to a lack of confidence, questionable motives and the criticism by PIs Personally I think we will see a small trial and a small raise. My fear is, however, by that time the share price will be through the floor. I do believe any hint of a delay will send the SP into yearly lows, partly created by the way in which the bod have dealt with the comms coupled with a fickle and impatient aim market Personally I will now sit on the side lines until clarity before adding, as I believe with any news other than approval we could see yearly lows. Raising funds would also be a concern at this stage, so again, clarity needed in due course Thanks to Ivy for insight into today’s AGM

It also comes down to **** poor comms and badly worded RNSs

Add that to size and scope of data required My fear is they are trying to be clever with covering bad news but only my opinion

Sufficiently funded to reach a decision point regarding Iclaprim based on the outcome of interactions with the FDA� IE when they receive minutes!!! That’s the decision. This is my point with this bod always trying to mislead and be clever to naive investors

That’s because it’s all bollcoks

Additional data likely will be required to address the Agency's concern about a risk of liver toxicity, the SIZE and SCOPE of which will determine the specific next steps Size and scope of what? The data? Can’t see how you can see size and scope of data given this would have already been issues (and issued after CRL before Type A). As I have thought all along, the bod know full well the score and this “wait for the minutes” doesn’t sit right with me personally And then adjourn the AGM what the feck is that all about on the day!!